Table 1 Clinical, demographic and laboratory characteristics of 72 SLE patients

 Age at study, years, mean (SD)

36.3 (8.9)

 Disease duration, years, median (range)

10 (0–32)

 SLEDAI-2 K, median (range)

2 (0–18)

 SLEDAI-2 K ≥1, n (%)

45 (63%)

 SLEDAI-2 K ≥4, n (%)

18 (25%)

 SLICC/ACR-DI, median (range)

0 (0–5)

 SLICC/ACR-DI ≥1, n (%)

25 (35%)

 NPSLE according to the ACR attribution model, n (%)

44 (61%)

 NPSLE according to the SLICC A attribution model, n (%)

16 (22%)

 NPSLE according to the SLICC B attribution model, n (%)

23 (32%)

 Ongoing glucocorticoid medication, n (%)

57 (79%)

 Ongoing anti-malarial medication, n (%)

57 (79%)

 Ongoing non-antimalarial DMARD medication, n (%)

43 (60%)

 Ongoing antihypertensive medication, n (%)

22 (31%)

 VAS Fatigue, median (range)

62 (1–100)

 Fatigue Severity Scale, median (range)

45 (0–63)

 S-Anti-dsDNA, titer ≥10, n (%)

15 (21%)

 S-Complement factor 3 < 0.8 g/L, n (%)

44 (61%)

 S-Complement factor 4 < 0.16 g/L, n (%)

52 (72%)

 aPL, n (%)

14 (19%)

 P-Creatinine, μg/L, mean (SD)

71 (14)

 eGFR, ml/min/1.73m², mean (SD)

99 (19)

 eGFR < 60 ml/min/1.73m², n (%)

2 (3%)